title: Ergocalciferol and cholecalciferol in CKD.
abstract: The development of chronic kidney disease (CKD) is accompanied by a progressive decrease in the ability to produce 1,25-dihydroxyvitamin D. Pharmacological replacement with active vitamin D therefore has been a cornerstone of secondary hyperparathyroidism therapy in the end-stage renal disease population treated by long-term dialysis. Recent evidence suggests that extrarenal conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D may have significant biological roles beyond those traditionally ascribed to vitamin D. Furthermore, low 25-hydroxyvitamin D levels are common in patients with all stages of CKD. This article focuses on the role of nutritional vitamin D replacement in CKD and aims to review vitamin D biology and summarize the existing literature regarding nutritional vitamin D replacement in these populations. Based on the current state of the evidence, we provide suggestions for clinical practice and address areas of uncertainty that need further research.
authors.affiliation: Division of Nephrology, Massachusetts General Hospital, Boston, USA.
authors.forename: Sagar U
authors.initials: SU
authors.lastname: Nigwekar
authors.forename: Ishir
authors.initials: I
authors.lastname: Bhan
authors.forename: Ravi
authors.initials: R
authors.lastname: Thadhani
mesh_terms: D000368:Aged; D002112:Calcifediol / Q000172:deficiency; D002762:Cholecalciferol; D004872:Ergocalciferols; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000628:therapy; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism; D014808:Vitamin D Deficiency / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D004872:Ergocalciferols; D014807:Vitamin D; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D; D002112:Calcifediol